Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) EPS (Basic) (2018 - 2025)

Inmune Bio (INMB) has disclosed EPS (Basic) for 8 consecutive years, with -$0.18 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 55.0% to -$0.18 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.9 through Dec 2025, up 9.95% year-over-year, with the annual reading at -$1.86 for FY2025, 11.85% up from the prior year.
  • EPS (Basic) hit -$0.18 in Q4 2025 for Inmune Bio, up from -$0.24 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.18 in Q4 2025 to a low of -$1.05 in Q2 2025.
  • Historically, EPS (Basic) has averaged -$0.45 across 5 years, with a median of -$0.43 in 2022.
  • Biggest five-year swings in EPS (Basic): plummeted 129.17% in 2021 and later surged 60.0% in 2025.
  • Year by year, EPS (Basic) stood at -$0.55 in 2021, then skyrocketed by 41.82% to -$0.32 in 2022, then crashed by 46.87% to -$0.47 in 2023, then increased by 14.89% to -$0.4 in 2024, then skyrocketed by 55.0% to -$0.18 in 2025.
  • Business Quant data shows EPS (Basic) for INMB at -$0.18 in Q4 2025, -$0.24 in Q3 2025, and -$1.05 in Q2 2025.